Dexamethasone dosing, mechanical ventilation and the risk of cerebral palsy

Objective. Risk factors for cerebral palsy (CP) in premature infants include duration of mechanical ventilation and exposure to postnatal dexamethasone (DEX). Since DEX can reduce the duration of mechanical ventilation, limited DEX exposure could be beneficial. Methods. This was a retrospective, cohort study of infants of less than 1500 g birth weight surviving to discharge between 1 January 1996 and 30 June 2001 who received postnatal dexamethasone. DEX administration was based only on the need for O2 and/or mechanical ventilation. CP was diagnosed at over 10 months post-conceptional age. Univariate and multivariate analyses were used to determine significant risk factors and the relative contribution of these factors to overall risk of CP. Results. Of 218 eligible infants 162 were followed-up (74%). The CP rate was 27.3%. Significant risk factors for CP included gestational age, ventilator duration, DEX dose, presence of periventricular leukomalacia (PVL), seizures, diagnosis of retinopathy of prematurity (ROP) and use of vasopressors. By multiple logistic regression, ventilator duration, PVL, grade III/IV intraventricular hemorrhage (IVH) and DEX dose were significantly related to CP. By stepwise multiple regression, grade III/IV IVH and ventilator duration were the strongest risk factors, but DEX dose continued to be a significant risk factor. Conclusions. The risk of CP was significantly related to the total cumulative dose of DEX. This could be due to a smaller exposure to DEX or to a reduced need for mechanical ventilation.

[1]  H. Aly.  Mechanical Ventilation and Cerebral Palsy , 2005, Pediatrics.

[2]  L. Doyle,et al.  Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease , 2005, Pediatrics.

[3]  R. Teele,et al.  A randomized trial of two dexamethasone regimens to reduce side‐effects in infants treated for chronic lung disease of prematurity , 2004, Journal of paediatrics and child health.

[4]  A. Jobe.  Postnatal corticosteroids for preterm infants--do what we say, not what we do. , 2004, The New England journal of medicine.

[5]  H. Hagberg,et al.  Sequelae of chorioamnionitis , 2002, Current opinion in infectious diseases.

[6]  Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. , 2002, Paediatrics & child health.

[7]  K. Barrington.  Postnatal steroids and neurodevelopmental outcomes: a problem in the making. , 2001, Pediatrics.

[8]  R. Ehrenkranz,et al.  Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[9]  A. Zaritsky,et al.  Early postnatal dexamethasone treatment and increased incidence of cerebral palsy , 2000, Archives of disease in childhood. Fetal and neonatal edition.

[10]  D. J. Goldstein,et al.  Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age , 1999, Pediatrics.

[11]  T. Pauly,et al.  A Three-day Course of Dexamethasone Therapy to Prevent Chronic Lung Disease in Ventilated Neonates: A Randomized Trial , 1999, Pediatrics.

[12]  T. O'Shea,et al.  Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants , 1999, Pediatrics.

[13]  A. Fanaroff,et al.  Perinatal Correlates of Cerebral Palsy and Other Neurologic Impairment Among Very Low Birth Weight Children , 1998, Pediatrics.

[14]  T. Yeh,et al.  Early dexamethasone therapy in preterm infants: a follow-up study. , 1998, Pediatrics.

[15]  T. O'Shea,et al.  Prenatal events and the risk of cerebral palsy in very low birth weight infants. , 1998, American journal of epidemiology.

[16]  T. O'Shea,et al.  Intrauterine infection and the risk of cerebral palsy in very low-birthweight infants. , 1998, Paediatric and perinatal epidemiology.

[17]  T. Yeh,et al.  Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. , 1997, Pediatrics.

[18]  H. Rozycki,et al.  Early versus late identification of infants at high risk of developing moderate to severe bronchopulmonary dysplasia , 1996, Pediatric pulmonology.

[19]  D. Elbourne,et al.  Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. , 1995, Pediatrics.

[20]  F. Mimouni,et al.  Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. , 1995, The Journal of pediatrics.

[21]  T. Yeh,et al.  Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. , 1990, The Journal of pediatrics.

[22]  J. Cummings,et al.  A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. , 1989, The New England journal of medicine.

[23]  D. S. Brudno,et al.  Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. , 1985, Pediatrics.